Plasma Derived Medicine Market, by Product Type (Albumin, Coagulation factors, Immunoglobulins, and Others), by Indication (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic

Plasma Derived Medicine Market, by Product Type (Albumin, Coagulation factors, Immunoglobulins, and Others), by Indication (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Infections, and Other Orphan Diseases), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Plasma-derived medicinal products are pharmaceuticals or medicines produced from human plasma which is the liquid portion of the blood and consists of approximately 90% water. It contains over 120 different proteins that take on functions vital to life, such as fighting infections or clotting of blood to stop bleeding after an injury. Albumin, immunoglobulin, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma. PDMPs (plasma-derived medicinal products) are used in medical treatment and prophylaxis. Plasma products play an important role in managing autoimmune disorders, bleeding emergencies, and a number of chronic conditions such as hemophilia, congenital and acquired immunodeficiencies, and other inherited protein disorders.
Market Dynamics
Increasing product approvals by regulatory bodies for plasma-derived medicines are expected to drive the global plasma derived medicine market over the forecast period. For instance, in July 2021, Octapharma AG, a company that develops and produces high-quality human proteins from human plasma and human cell lines, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its Octagam 10%, an immune globulin intravenous (human) liquid preparation derived from large pools of human plasma, the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
Moreover, increasing marketing approvals by the regulatory bodies for plasma-derived medicines is expected to drive the global plasma derived medicine market over the forecast period. For instance, in January 2022, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, announced that the National Medical Products Administration (NMPA) for China granted BPL a license to market ALBUMINEX 25% product in China.
Key features of the study:
This report provides an in-depth analysis of the global plasma derived medicine market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasma derived medicine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global plasma derived medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma derived medicine market
Detailed Segmentation:
Global Plasma Derived Medicine Market, By Product Type:
Albumin
Coagulation factors
Immunoglobulins
Others
Global Plasma Derived Medicine Market, By Indication:
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
Global Plasma Derived Medicine Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Plasma Derived Medicine Market, By Region:
North America
By Product Type
Albumin
Coagulation factors
Immunoglobulins
Others
By Indication
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Product Type
Albumin
Coagulation factors
Immunoglobulins
Others
By Indication
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Albumin
Coagulation factors
Immunoglobulins
Others
By Indication
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Albumin
Coagulation factors
Immunoglobulins
Others
By Indication
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Albumin
Coagulation factors
Immunoglobulins
Others
By Indication
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Albumin
Coagulation factors
Immunoglobulins
Others
By Indication
Pelvic Inflammatory Disease (PID)
Bleeding Disorders
Alpha-1 Antitrypsin Deficiency (AATD)
Hereditary Angioedema (HAE)
Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barre Syndrome
Multifocal Motor Neuropathy
Liver Diseases
Primary Immune Thrombocytopenia
Infections
Other Orphan Diseases
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Grifols, S.A.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
SK Plasma
Fusion Healthcare
Takeda Pharmaceutical Company Limited
LFB
Octapharma AG
CSL Limited
Bio Products Laboratory Ltd.
China Biologic Products Holdings, Inc.
Kedrion
Shanghai RAAS
ADMA Biologics Inc.
Kamada Pharmaceuticals
Biotest AG
“*” marked represents similar segmentation in other categories in the respective section.